Notification of Director Incharge of CDL Kolkata

## Policy Analysis Report: Notification Regarding Statutory Certificates of Test or Analysis for Drugs and Cosmetics **1. Executive Summary:** This report analyzes a notification issued by the Ministry of Health and Family Welfare, Government of India, dated August 10, 2022. This notification authorizes Dr. Saroj Kumar Ghosh, Director Incharge of Central Drugs Laboratory (CDL), Kolkata, to sign statutory certificates of test or analysis for drugs and cosmetics samples sent by Courts of Law under specified sections of the Drugs and Cosmetics Act, 1940. However, this authorization excludes specific classes of drugs and medical devices (e.g., sera, vaccines, blood products, condoms). The notification aims to ensure the continued issuance of statutory certificates during the interim period until a regularly appointed Director takes charge. **2. Introduction:** This report provides a detailed analysis of a notification published by the Ministry of Health and Family Welfare, Government of India, on August 10, 2022, concerning the authorization of a Director Incharge to sign statutory certificates for drugs and cosmetics. The analysis is based solely on the information contained within the provided notification text. **3. Policy Overview:** * This notification supersedes the previous notification S.O. 2662(E) dated October 31, 2012, published in the Gazette of India, Extraordinary, Part II, section 3, subsection ii, with exceptions for actions already completed or omitted before this supersession. * **Core Objective:** The core objective, inferred from the text, is to ensure the uninterrupted issuance of statutory certificates of test or analysis for drug and cosmetic samples submitted by Courts of Law, as mandated by the Drugs and Cosmetics Act, 1940. This is achieved by authorizing a specific individual to fulfill this role during a transitional period. **4. Background and Rationale:** The notification addresses a potential disruption in the issuance of statutory certificates due to a vacancy in the position of Director at the Central Drugs Laboratory (CDL), Kolkata. The authorization of the Director Incharge serves as a temporary measure to maintain the operational efficiency of the drug and cosmetic regulatory system, specifically concerning the legal aspects of drug and cosmetic testing. **5. Key Provisions / Changes:** * **Supersession:** The notification supersedes S.O. 2662(E), dated the 31st October, 2012. This suggests a change in the authorized signatory compared to the previous notification. * **Authorization:** The key change introduced by this notification is the authorization of Dr. Saroj Kumar Ghosh, Director Incharge of CDL, Kolkata, to sign statutory certificates of test or analysis. * **Scope:** This authorization is specific to samples of drugs and cosmetics sent by Courts of Law under subsection 4 of section 25 of the Drugs and Cosmetics Act, 1940, or in Form 1 of the Drugs Rules, 1945, for the whole of India. * **Duration:** The authorization is temporary, effective from the date of publication in the Official Gazette until a regularly appointed person assumes the post or until further orders are issued, whichever is earlier. * **Exclusions:** The authorization explicitly excludes certain classes of drugs and medical devices. The excluded items are: 1. Sera 2. Solution of Serum Proteins intended for injection 3. Vaccines 4. Toxins 5. Antigens 6. Antitoxins 7. Sterilised surgical ligature and sterilised suture 8. Bacteriophages 9. AntiSera for Veterinary use 10. Vaccines for Veterinary use 11. Toxoids for Veterinary use 12. Diagnostic Antigens for Veterinary use 13. VDRL Antigen 14. IntraUterine Devices and Falope Rings 15. Human Blood and Human Blood Products 16. Blood Grouping reagents and diagnostics kits for Human Immunodeficiency Virus, Hepatitis B Surface Antigen and Hepatitis C Virus 17. Condoms **6. Target Audience and Stakeholders:** The primary target audience and stakeholders affected by this notification include: * **Central Drugs Laboratory (CDL), Kolkata:** The notification directly impacts the operations and responsibilities of the CDL. * **Courts of Law:** Courts relying on drug and cosmetic test reports in legal proceedings are affected. * **Manufacturers and Distributors of Drugs and Cosmetics (excluding those in the listed excluded items):** Entities whose products are subject to legal scrutiny and require testing by the CDL. * **Regulatory Agencies:** Agencies involved in the enforcement of the Drugs and Cosmetics Act, 1940. **7. Implementation Aspects (Inferred):** * **Responsible Agency:** The Ministry of Health and Family Welfare, Department of Health and Family Welfare, is the responsible agency. The Central Drugs Laboratory, Kolkata, is the implementing body. * **Timeline:** The notification is effective from the date of its publication in the Official Gazette (August 10, 2022) and remains in effect until a regularly appointed Director assumes the post or until further orders are issued. * **Procedure:** The Director Incharge is now authorized to sign certificates for the specified drug and cosmetic samples received from Courts of Law. This maintains the pre-existing procedure, ensuring continuity. The exclusions mean that for those specific products, presumably another authorized signatory would be required. **8. Expected Outcomes / Impact of Changes:** The intended outcome of this notification is to prevent delays and maintain the integrity of the drug and cosmetic regulatory system by ensuring the continuous availability of legally valid test and analysis certificates during the interim period. This will facilitate the smooth processing of legal cases involving drugs and cosmetics. The impact specifically will be on Drugs & Cosmetics manufacturers (excluding listed classes) that are involved in court cases, for which CDL Kolkata analysis results are submitted as part of the legal proceedings. **9. Conclusion:** The notification issued by the Ministry of Health and Family Welfare on August 10, 2022, is a crucial administrative measure designed to maintain the continuity of drug and cosmetic regulation. By authorizing the Director Incharge of CDL, Kolkata, to sign statutory certificates, the government addresses a potential bottleneck in the legal process related to drug and cosmetic quality control and ensures ongoing compliance with the Drugs and Cosmetics Act, 1940. The temporary nature of the authorization and the explicit exclusions for specific classes of drugs and devices highlight the focused and targeted nature of this policy adjustment.

Key Entities Referenced